$XLO insiders have traded $XLO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Stay updated on market trends for XLO. Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? AbbVie and Xilio partner to develop tumor-activated immunotherapies.

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. (ABBV). The two companies announced a collaboration and option-to ...

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology ...

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) increased during the last reporting period, rising from 199.05K to 1.81M. This put 4.26% of the company's publicly available shares short.

A number of institutional investors have recently bought and sold shares of XLO. Geode Capital Management LLC increased its position in Xilio Therapeutics by 85.0% in the third quarter.